Serum β2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 571-577

  Okuno, Senji ^a   Ishimura, Eiji ^b   Kohno, Kaori ^a   Fujino Katoh, Yoko ^a   Maeno, Yoshifumi ^a   Yamakawa, Tomoyuki ^a   Inaba, Masaaki ^b   Nishizawa, Yoshiki ^b  

^a OSAKA CITY UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

2 microglobulin; Haemodialysis; Mortality; Non cardiovascular mortality

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; TOXIN; UREMIA MIDDLE MOLECULE TOXINS;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC GLOMERULONEPHRITIS; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CHRONIC KIDNEY FAILURE; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY;

AGED; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; TOXINS, BIOLOGICAL;

EID: 58449097638     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn521     Document Type: Article

References (36)

1. Orlando RA, Rader K, Authier F et al. Megalin is an endocytic receptor for insulin. J Am Soc Nephrol 1998; 9: 1759-1766
2. Lonnemann G, Koch KM. Beta(2)-microglobulin amyloidosis: effects of ultrapure dialysate and type of dialyzer membrane. J Am Soc Nephrol 2002; 13(Suppl 1): S72-S77
3. Kazama JJ, Maruyama H, Gejyo F. Reduction of circulating beta2-microglobulin level for the treatment of dialysis-related amyloidosis. Nephrol Dial Transplant 2001; 16(Suppl 4): 31-35
4. Bolasco P, Altieri P, Andrulli S et al. Convection versus diffusion in dialysis: an Italian prospective multicentre study. Nephrol Dial Transplant 2003; 18(Suppl 7): vii50-vii54; discussion (vii59-vii62)
5. Locatelli F, Di Filippo S, Manzoni C. Removal of small and middle molecules by convective techniques. Nephrol Dial Transplant 2000; 15(Suppl 2): 37-44
6. Fry AC, Singh DK, Chandna SM et al. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif 2007; 25: 295-302
7. Cheung AK, Rocco MV, Yan G et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17: 546-555
8. Cheung AK, Levin NW, Greene T et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003; 14: 3251-3263
9. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213
10. Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec. 31, 2002. Japanese Society for Dialysis Therapy, Tokyo, 2003
11. Bernard AM, Vyskocil A, Lauwerys RR. Determination of beta 2-microglobulin in human urine and serum by latex immunoassay. Clin Chem 1981; 27: 832-837
12. Kakiya R, Shoji T, Tsujimoto Y et al. Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int 2006; 70: 549-556
13. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184
14. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943
15. Drueke TB. Beta2-microglobulin and amyloidosis. Nephrol Dial Transplant 2000; 15(Suppl 1): 17-24
16. Tattersall J. Clearance of beta-2-microglobulin and middle molecules in haemodiafiltration. Contrib Nephrol 2007; 158: 201-209
17. Goldfarb-Rumyantzev AS, Leypoldt JK, Nelson N et al. A crossover study of short daily haemodialysis. Nephrol Dial Transplant 2006; 21: 166-175
18. Vanholder R, Laecke SV, Verbeke F et al. Uraemic toxins and cardiovascular disease: in vitro research versus clinical studies. Nephrol Dial Transplant Plus 2008; 1: 2-10
19. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
20. Hakim RM, Held PJ, Stannard DC et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50: 566-570
21. Canaud B, Assounga A, Flavier JL et al. Beta-2 microglobulin serum levels in maintenance dialysis. What does it mean? ASAIO Trans 1988; 34: 923-929
22. Charra B, Laurent G, Calemard E et al. Serum beta2-microglobulin (beta2-MG) decrease in hemodialysis (HD) patients: a long-term follow-up. Blood Purif 1988; 7: 249-250
23. Koda Y, Nishi S, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096-1101
24. Port FK, Wolfe RA, Hulbert-Shearon TE et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis 2001; 37: 276-286
25. Woods HF, Nandakumar M. Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 2000; 15(Suppl 1): 36-42
26. Chauveau P, Nguyen H, Combe C et al. Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005; 45: 565-571
27. Wizemann V, Lotz C, Techert F et al. On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. Nephrol Dial Transplant 2000; 15(Suppl 1): 43-48
28. Canaud B, Bragg-Gresham JL, Marshall MR et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69: 2087-2093
29. Jirka T, Cesare S, Di Benedetto A et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis. Kidney Int 2006; 70: 1524; author reply 1524-1525
30. Coyne DW, Dagogo-Jack S, Klein S et al. High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients. Am J Kidney Dis 1998; 32: 1031-1035
31. Haag-Weber M, Mai B, Cohen G et al. GIP and DIP: a new view of uraemic toxicity. Nephrol Dial Transplant 1994; 9: 346-347
32. Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17(Suppl 8): 29-32; discussion 39-40.
33. Yeun JY, Levine RA, Mantadilok V et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476
34. den Elzen WP, van Manen JG, Boeschoten EW et al. The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant 2006; 21: 1588-1595
35. Cheung AK, Greene T, Leypoldt JK et al. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 69-77
36. Leypoldt JK. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration. Semin Dial 2005; 18: 401-408